Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 21-04-15 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 21-04-15 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 21-04-15 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +1.03% | +2.30% | +55.91% | +114.22% | 56.42B | |
| +2.72% | +3.26% | +46.05% | +44.91% | 44.54B | |
| +1.12% | +2.79% | -15.04% | -21.68% | 22.9B | |
| +1.17% | +3.85% | -0.89% | +403.86% | 21.21B | |
| +3.81% | -5.07% | +11.00% | -30.62% | 16.4B | |
| +0.15% | +2.24% | +9.32% | -39.30% | 15.4B | |
| -0.69% | +0.82% | +27.75% | +176.72% | 13.35B | |
| +5.27% | +5.54% | +19.65% | - | 12.36B | |
| +1.61% | +1.28% | +95.75% | +205.26% | 11.15B | |
| Average | +1.62% | +2.09% | +27.72% | +106.67% | 23.75B | |
| Weighted average by Cap. | +1.71% | +2.37% | +32.04% | +99.60% |
Employees
51
